Please login to the form below

Not currently logged in
Email:
Password:

The Saatchi & Saatchi Health Award for Launch Excellence

Sponsored by

Finalist

Simponi Launch

MSD


Summary of work

Over 800,000 people in the UK suffer from seriously debilitating auto‐immune diseases of which Rheumatoid Arthritis is one. These conditions can physically disable patients and dramatically impact upon their quality of life.

Anti-Tumour Necrosis Factor (anti‐TNF) drugs have been successfully used over the past 10 years to transform the lives of patients.

The challenge for MSD Immunology was to launch a new anti-TNF Simponi (golimumab) into a highly competitive market where MSD already had an existing anti‐TNF, Remicade (infliximab) still showing double-digit growth 12 years post-launch. 

A co‐positioning strategy was developed for the two brands to be sold alongside each other to present a franchise approach.

A new salesforce structure was put in place to enable Simponi to be launched across three indications, Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. NICE approval was gained for all licensed indications.

The launch strategy was informed by comprehensive customer insights through a variety of qualitative and quantitative market research across all stakeholder groups (payers, prescribers, patients, and support staff).

Objectives and metrics were set prior to launch which would have to be met if Simponi was to achieve an excellent launch.

By the end of 2011 all launch objectives for Simponi were met or exceeded. Remicade also continued to grow in line with plan.

 

 

Executive summary as submitted


COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....